ReNerve

ASX Announcement

22 September 2025

Empliq tissue product range launched

ReNerve Limited (ASX, "**ReNerve**" or "the **Company**"), an ASX listed medical device company developing innovative products for peripheral nerve injury ("**PNI**") repair, is pleased to announce that it has successfully launched its Empliq range (see attached slide deck for further information) after recently completing first sales of the human tissue products.

The new product range is now available in the US, with ReNerve to implement market launch activities at the upcoming American Society for Surgery of the Hand (ASSH) conference in Vancouver in the first half of October.

Developed in conjunction with its partner Berkeley Biologics, the product range is complementary to the existing ReNerve product portfolio, focusing on a range of indications already targeted by ReNerve.

The first sale, of the Empliq Dermal deep-layer matrix product, precedes the amniotic and placental allograft products reaching the market in Q3 CY25.

"The launch of the Empliq range is a key step in our strategy to provide a broad suite of products to surgeons, whilst it complements our existing nerve repair product range. We've developed and completed all the branding and marketing materials for Empliq , and the products are now available to our sales teams across the US. We look forward to bringing continued updates as we see the traction Empliq gains in the market," **said ReNerve CEO Dr Julian Chick.**

The dermal and amniotic tissue market is estimated to reach more than $1.5 billion in 2026 and more than $3 billion by 2032.[1]

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

[1] MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product --** A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges --** Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – Eliminating the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.96 billion in 2024 and is projected to reach $6.2 billion by 2031.[2]

[2] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.